SOPHiA GENETICS Reports Financial Results for the Second Quarter of Fiscal 2023
Retrieved on:
Tuesday, August 8, 2023
Operating cost, White House, Tulane University School of Medicine, Eastern Time Zone, Education, Central European Summer Time, Marketing, NGS, COVID-19, Microsoft, H. Lee Moffitt Cancer Center & Research Institute, Research, COVID, Biomarker, History, Forecasting, White, Sophia, Constant, Sophia Genetics, Lila Tretikov, Blood, Memorial Sloan Kettering Cancer Center, GENETICS, Corporation, Cancer Moonshot, Artificial intelligence, Growth, Annual general meeting, Video game, Pharmaceutical industry, Wikimedia Foundation
Gross margin was 67% for the second quarter of 2023 compared with 65% for the second quarter of 2022.
Key Points:
- Gross margin was 67% for the second quarter of 2023 compared with 65% for the second quarter of 2022.
- Adjusted gross margin was 70% for the second quarter of 2023 compared to 67% for the second quarter of 2022.
- R&D expenses for the second quarter of 2023 were $8.9 million compared to $9.0 million for the second quarter of 2022.
- Operating loss for the second quarter of 2023 was $20.0 million compared to $24.1 million in the second quarter of 2022.